Health insurance: Who is best at claims settlement?

With inputs from Bipin Ramachandran.

If you’re looking to choose a health insurance plan, the most important metric to look at is the insurer’s track record on paying claims. Indian health insurers tend to be slippery as eels when it comes to settling your bills.

The industry receives lakhs of customer complaints every year on rejected, repudiated and partly disallowed claims. We’ve discussed some reasons health insurers may reject claims earlier.

But how can you gauge a health insurer’s claims record? The data to make this assessment is not easy to find, as health insurers keep their claims numbers a closely guarded secret. IRDA, which used to compile this data in its annual reports until three years ago, has taken to blanking it out too.

Health insurance  best at claims settlement

At PrimeInvestor, we assign a high weight to an insurer’s claims settlement record in the Prime Health Insurance recommendations. Every year, we manually compile claims data from each individual insurer’s statutory disclosures. 

We decided to publish this exclusive, hard-to-find data for your ready reference. We also explain how you should interpret it!

How they stack up

The table below ranks general and standalone health insurance companies based on their claims settlement ratios for FY24. FY23 numbers are also presented so you can evaluate consistency.

Here’s what the three ratios mean. 

  • Claims settlement by number: This is the number of claims that the insurer has paid in the financial year compared to the total number of claims it received and carried forward from the previous year. 
  • Claims settlement by value:  This is the rupee value of claims paid by the insurer compared to the rupee value of the claims it received and carried forward from the previous year. 
  • Claims efficiency ratio: Of the claims that the insurer has paid, how many were paid within 3 months? This is captured in the claims settlement efficiency ratio. 

How to read them

Health insurance buyers are often confused about what metric to look at when evaluating if a health insurer will keep its promise. So here are some tips on how you should read the above data.

Rejection vs repudiation:

When you file a claim with a health insurance company, it does not always admit it for further processing. Insurers ‘reject’ a fair number of claims soon after receiving them, for incomplete documentation, data errors, incorrect entries and so on. The official data on claims settlement provided by insurers does not capture the claims that are not admitted at all, due to deficiencies in paperwork. They only capture the claims that are declined after being admitted - this is called repudiation. 

For instance, say an insurer received 1000 claims, rejected 200 for clerical errors and settled 600 of those claims within the year. Its claim settlement ratio will be 75% (600/800) and not 60% (600/1000). The claims settlement ratio is thus likely to be overstating the probability of your bill being paid by the insurer.

ICR is irrelevant:

Recently, the health insurance industry has been promoting the Incurred Claims Ratio or ICR, as the number that policyholders must check before signing up for a health plan. This is a diversionary tactic. 

ICR measures the claims paid out by the insurer as a proportion of the premiums it has collected in a specific period. ICR tells you whether the insurer paid out more money in a particular period than the premiums it collected. During Covid for instance, most health insurers had ICRs above 100% because they were paying out more claims than premiums collected. Post-Covid, their ICRs have dropped below 90%. 


The ICR is a rough gauge of an insurer’s profitability, not claims record. An investor may like to buy shares of an insurance company with a low ICR. But the ICR is of little value to the health policy buyer - who should be focussing on whether the insurer is in the habit of settling claims. In fact, an insurer with low ICR should be a red flag to policy buyers, because it shows the insurer loves to rake in premiums while economising on paying claims. 

Claims by value:

Many folks choose their health insurance plan based on the claims settlement ratio (CSR) by number. They assume that if an insurer has a 90% CSR by number, they have a 9 in 10 chance of getting their bills reimbursed. But this is very misleading because insurers very often settle only part of the claim you file with them. It is routine practise for insurers to disallow some items of expenses from your hospital bill – the cost of consumables, room and other associated charges beyond policy sub-limits etc. 

This is where CSR by value comes in. The data we shared above shows you that many insurers manage a CSR by number ratio above 90%, but only a few manage a CSR by value ratio that is above 90%. In FY24, 14 of 27 insurers had a CSR ratio of over 90% by number, but only 7 of 27 insurers had a CSR of over 90% by value, showing that they settled a large proportion of the bills admitted by them.  

This is why CSR by value is the key metric to look at while choosing a health insurer. It helps you weed out insurers who settle your claim on paper but leave a large part of your hospital bills uncovered.

PSU versus private insurers

The conventional wisdom on health insurance is that PSU insurers are not a good choice because they impose sub-limits on your room and treatment charges, and have co-payment clauses that result in only partial settlement of your bills. Private health insurers on the other hand, have no sub-limits on rooms, diseases or co-payment clauses. 

But the data on CSR shows that PSU insurers score very high on the CSR by value ratio, with all of them settling over 95% of claims by value. The gaps between their CSR ratios by value and number are also not very large. 

This indicates that PSU insurers offer greater certainty of claims payment, by settling most of the claims that they admit after enforcing sub-limits, co-payment clauses etc. Private insurers, on the other hand, seem to be compensating for their no sub-limit and co-payment clauses through poorer CSRs by value. 

This goes to show that if you’re buying a health insurance policy, you can’t go wholly by product features such as no co-payment, no sub-limits etc. Product features need to be evaluated along with the insurer’s willingness to fully pay claims. 

This is why we give PSU insurers equal consideration in our product rankings and consideration. We have a mix of products from both private and PSU insurers in our health insurance recommendations

Note: The claim ratios are calculated from public disclosures of individual insurers. In case there is an error in calculation using claim settlement values, claim repudiation values are used to indirectly calculate claim settlement ratios.

More like this

38 thoughts on “Health insurance: Who is best at claims settlement?”

  1. Aarati Madam,
    Nice article. I like that there are always some Action-able pointers in your articles 🙂
    Was not aware of CSR(V) before your article
    Thank you

  2. Hello Aarati mam,
    Nice article.
    Kindly clarify one doubt.

    I am in process of obtaining separate health insurance policy, apart from employer coverage. My financial advisor recommends, HDFC ergo optima secure (mainly due to multiplier benefits) not to consider optima Restore at current scenario. As coincidence, this article recommends restore policy, so kindly guide to clarify, which one to consider.

  3. Thank you for the informative report.

    I have an individual 15L Care Supreme policy (restore one) (just ported out of Niva reAssure). Is it advisable to take a super top-up (I am in my mid 30s)? If so, should one consider a super top-up from the same insurer or different?

    Why had HDFC Ergo been considered in super top-up? Asking because they offer a super top maxing at 20L. That seems a bit out of place seeing today’s medical inflation, won’t you say so? A survey or some data on what is the average SI of PI customers might have given some pointer to be honest (because that is whom the article is for, right?).

    Also, I see Star and Bajaj Allianz in base health policies. I have had experience with Star (for relatives) and was nightmarish and I tried asking friends and colleagues and they said Star should summarily be avoided. I do not question your report because my assumption is you would have gone by just number/facts. But given the limited numbers and what they project is it advisable to take these numbers at face value, just like we should not consider ICR at all? Have not heard or read good things about Bajaj either.

    Again, appreciate the report. This is the first time I looked at it from the CSR(V) angle ever! So thank you for that 🙏

    1. Thanks for raising this. Yes we are aware of the limitations of going by numbers when it comes to health insurance and have been trying to arrive at a solution. HDFC ergo and National figure in our recos due to their relatively better claims record. It does make sense to take a super topup. We are working on a research piece on this, so kindly wait for it.

  4. very informative data. While ICICI Lombard seems to have recently launched an attractive plan under the name elevate – the data on claim settlement by value shows a pretty poor picture on them.
    What could be the reason for inconsistency across years for some others – eg. Tata AIG the variance across FY24 and FY23 is around 10% across both CS value and number. In genernal companies dont overnight become more lenient and behave in a consistent manner across years. Is there a way to assess this data better?

  5. Very informative article.

    I am planning to buy a new insurance policy in a week and stop paying premium for existing insurance policy which is due in a week.
    I want to know if there will be change in recommendations based on CSR by value. I was thinking of buying ICICI health insurance recommended by primeinvestor but wanted to know if there will be change in recommendations based on this data.

  6. Preferably Anonymous

    From personal experience, Star Health refused to pay out a valid claim repeatedly asking for non-existent nonsensical documents. Changed to National Insurance and they were much better on another claim. They reimbursed but amount received was only about 50%.

    Health insurance is largely a scam. Putting you through tedious paperwork and running around when you’re at your most vulnerable. And never fully serving its purpose when you need it most. You can pay premiums for a lifetime and then they never come through when you finally need it because of some ridiculous clause they inserted halfway 20 years after you signed up or they exhaust you with claims procedures and paperwork when you’re ill and hospitalized.

    Now we have a “Health Insurance Fund” that keeps growing on top of our insurance plan.

      1. Aarti please extend your suggestions for an health fund construction being self sufficient , as It’s irony that insurance is given / taken for an healthy adult and regretted for aged members and if any claim not even application is entertained , premium ceiling comes into play etc

  7. Hi Aarati,
    I hear … Many reputed and private hospitals do not entertain ‘cashless’ admissions against PSU insurance as the insurer takes irrationally long time to settle payments to the hospitals.

    How true is this..? My personal experience with New India Assurance has been very pleasant wrt claim reimbursement post payment at the hospital.

    Regards… Jatin

    1. I really do not think so. I have Oriental Insurance for my family since last 26 years and the experience has been good in hopitals like Apollo & Fortis. Cash less settlement is very smooth. I haven’t had any issues with them. My wife has developed hypertension & diabetes, I informed them on email with the test reports & the medications she is taking during the renewal of the policy. They accepted it without increasing the premium for family floater & top up. Even for procedures which do not require hospitialisation they have paid in full.

  8. Vittal Venugopal

    Thanks Aarti, Very nice article and an eye opener. I used to think that CSR by number is better, now got a new perspective. I had PSU health insurance and was thinking of porting to private health insurer. Now staying put with my current health insurance which has a very high CSR by value and number.

      1. I’m not writing this comment to educate Ms. Aarati Krishnan or other informed people, but to inform all the other people who are not fully aware of PSU insurers.

        I’ve read all the comments on PSU insurers. They are not all that great. The 1% of SI room rent capping clause is the biggest spoiler/let-down with PSU insurers. If your SI is 3 lakh for instance, you can take a room only for Rs. 3,000 per day (1% of SI). For instance, If you take a room for Rs.4,500 (50% more room rent than the allowed 1% of SI) then 50% of the ENTIRE CLAIM will be forfeited. In what way is this fair? If a person gets insured for just 1 lakh, they might not get any claim, because in most hospitals even general ward charges more than Rs. 1000 a day.

        The only way out of this is to have a higher sum assured by paying a higher premium at the time of taking the policy itself. Because, when I approached the PSU insurer they are very reluctant to increase the SI even by 50,000 or 1 lakh, especially even if you made a minor claim in previous year/s.

        And if they DO agree to increase the SI, there is a two year waiting period for the increased SI to kick-in. So it might take even 10 years for one to increase their SI from say 4 lakh to 10 lakh, that is if they DO agree to increase it. The quantum of allowed increase in SI is decided based on your age and previous claims history. PSU insurers have a highly prejudiced, judgmental and unfair system that doesn’t work in times of emergencies for many people. And they don’t go by the rules and IRDA norms. Its all based on their cash position and profit that particular year. We are not asking anything that is illegal or what the rules and regulations don’t allow!

        Also, they keep changing clauses every year. They paid only 50% for my claim although there was no sub-limit for the particular surgery, even though I was within the 1% room-rent capping limit. I escalated as a grievance to higher authorities but they would not give any reason why only 50% of claim was paid. Also, they have TPAs with poor customer care, and some cant even understand the language we speak – even English. Customer care of TPAs is very poor. The PSU insurer’s TPAs work only to favour the insurers and not the common man.

        1. Thank you for sharing your experience. Yes PSU insurers have room sub limits and other red tape that reduce your SI and reimbursement. But people have equally bad experiences to recount about private insurers. They market their products saying no sub limits and promote large SI upto Rs 1 crore, but then fail to pay even fraction of the SI as claim. TPAs are bad across insurers. It’s a tough choice but what to do, health insurance is an essential product!

          1. Mam, thank you for being empathetic about my experience with health insurance. However, Primeinvestor has been a huge help in my life in managing my finances. I avoided a lot of losses by reading primeinvestor articles. I’ve been subscribing for last few years. Best wishes to you and our entire PI community.

          2. Hi Aarati.

            How does that factor in in CSR(Value)?

            Let’s say actual room rent was 8000 per night (which is not unheard of today but just an example) and due to SI’s x% limit, again for example, only 4000 was paid and hence every other expenses (or most) at 50% then what is that considered in CSR (Value)? 100% paid or only 50% paid? Because as you can see — from the insurer’s angle they paid 100% “eligible” amount but for insured’s angle the payment was only 50%. Not commenting and saying whether private is bad or PSU, just to understand how CSR (value) might have actually been calculated.

Leave a Comment

Hold On

You are being redirected to another page,
it may take a few seconds.
Login to your account
OR

Become a PrimeInvestor!

Get stock & mutual fund recommendations

Start registration

Start registration

OR
user icon
user icon
user icon

Terms & Conditions

A copy of the T&C has been sent to your email.

Last modified on February 18, 2025

This website www.primeinvestor.in (“Website”) is owned and operated by PrimeInvestor Financial Research Pvt. Ltd. (“RA”), a SEBI-registered Research Analyst with Registration No. INH200008653.

Through the Website, the RA allows clients to access research recommendations, research reports, and model portfolios, along with tools, personal finance products, and articles, on the payment of a subscription fee (“Research Services”). The terms ‘RA’ or ‘us’ or ‘we’ refer to PrimeInvestor Financial Research Pvt Ltd (SEBI RA Registration No INH200008653) who are the owners of this Website and offering the Research Services. The term ‘you’ and ‘client’ refers to the subscriber of the Services on the Website. The RA provides the Research Services subject to the notices, terms, and conditions set forth in these Terms. By accepting these Terms when you subscribe to the Research Services, you provide your consent to abide by these Terms.

Most Important Terms and Conditions (MITC)

[Forming part of the Terms and Conditions for providing research services]

  1. These terms and conditions, and consent thereon are for the research services provided by the Research Analyst (RA) and RA cannot execute/carry out any trade (purchase/sell transaction) on behalf of the client. Thus, the clients are advised not to permit RA to execute any trade on their behalf.
  2. The fee charged by RA to the client will be subject to the maximum amount prescribed by SEBI/ Research Analyst Administration and Supervisory Body (RAASB) from time to time (applicable only for Individual and HUF Clients).
    Note:
    • SEBI's current cap on fee is Rs 1,51,000/- per annum per family of client for all research services of the RA.
    • The fee limit does not include statutory charges.
    • The fee limits do not apply to a non-individual client / accredited investor.
  3. RA may charge fees in advance if agreed by the client. Such advance shall not exceed the period stipulated by SEBI; presently it is one quarter. In case of pre-mature termination of the RA services by either the client or the RA, the client shall be entitled to seek refund of proportionate fees only for the unexpired period.
  4. Fees to RA may be paid by the client through any of the specified modes like cheque, online bank transfer, UPI, etc. Cash payment is not allowed. Optionally the client can make payments through Centralized Fee Collection Mechanism (CeFCoM) managed by BSE Limited (i.e. currently recognized RAASB).
  5. The RA is required to abide by the applicable regulations/ circulars/ directions specified by SEBI and RAASB from time to time in relation to disclosure and mitigation of any actual or potential conflict of interest. The RA will endeavor to promptly inform the client of any conflict of interest that may affect the services being rendered to the client.
  6. Any assured/guaranteed/fixed returns schemes or any other schemes of similar nature are prohibited by law. No scheme of this nature shall be offered to the client by the RA.
  7. The RA cannot guarantee returns, profits, accuracy, or risk-free investments from the use of the RA's research services. All opinions, projections, estimates of the RA are based on the analysis of available data under certain assumptions as of the date of preparation/publication of research report.
  8. Any investment made based on recommendations in research reports are subject to market risks, and recommendations do not provide any assurance of returns. There is no recourse to claim any losses incurred on the investments made based on the recommendations in the research report. Any reliance placed on the research report provided by the RA shall be as per the client's own judgement and assessment of the conclusions contained in the research report.
  9. The SEBI registration, Enlistment with RAASB, and NISM certification do not guarantee the performance of the RA or assure any returns to the client.
  10. For any grievances,
    • Step 1: the client should first contact the RA using the details on its website or following contact details:
      Customer care: [email protected]
      Grievance officer: [email protected], ATTN: Srikanth Meenakshi
      Compliance officer: [email protected], ATTN.: Bhavana Acharya
      Principal officer: [email protected], ATTN.: Vidya Bala
    • Step 2: If the resolution is unsatisfactory, the client can also lodge grievances through SEBI's SCORES platform at www.scores.sebi.gov.in
    • Step 3: The client may also consider the Online Dispute Resolution (ODR) through the Smart ODR portal at https://smartodr.in
  11. Clients are required to keep contact details, including email id and mobile number/s updated with the RA at all times.
  12. The RA shall never ask for the client’s login credentials and OTPs for the client’s Trading Account, Demat Account, and Bank Account. Never share such information with anyone including RA.

By browsing, viewing, using the Website and subscribing to the Research Services provided therein you consent to and agree to comply with these Terms and Conditions of subscription (“Terms”).

The RA reserves the right to change or modify the Website, the contents thereof and these Terms at any time. All modifications to these Terms & Conditions will be posted on the Website and will become effective immediately upon such posting. Changes once made will be communicated to the client. Continued use of the Website shall be construed as acceptance of the revisions to the Terms by conduct.

The following terms and conditions include but are not limited to minimum mandatory terms and conditions to clients as stipulated by SEBI.

1. Availing the research services

By accepting delivery of the research service, the client confirms that he/she has elected to subscribe to the research service of the RA at his/her sole discretion. The RA confirms that Research Services shall be rendered in accordance with the applicable provisions of the SEBI RA Regulations.

2. Obligations on RA

The RA shall be bound by the SEBI Act and all the applicable rules and regulations of SEBI, including the RA Regulations and relevant notifications of Government, as may be in force, from time to time.

3. Client Information and KYC

The client shall furnish all such details in full as may be required by the RA in its standard form with supporting details, if required, as may be made mandatory by Research Analyst Administration and Supervisory Body(RAASB)/SEBI from time to time. RA shall collect, store, upload and check KYC records of the clients with KYC Registration Agency (KRA) as specified by SEBI from time to time.

4. Standard Terms of Service

The consent of client shall be taken on the following understanding:

“I / We have read and understood the terms and conditions applicable to a research analyst as defined under regulation 2(1)(u) of the SEBI (Research Analyst) Regulations, 2014, including the fee structure.

I/We are subscribing to the research services for our own benefits and consumption, and any reliance placed on the research report provided by research analyst shall be as per our own judgement and assessment of the conclusions contained in the research report.

I/We understand that –

  1. Any investment made based on the recommendations in the research report are subject to market risk.
  2. Recommendations in the research report do not provide any assurance of returns.
  3. There is no recourse to claim any losses incurred on the investments made based on the recommendations in the research report.”

The declaration of the RA is as follows:

  1. We are duly registered with SEBI as an RA pursuant to the SEBI (Research Analysts) Regulations, 2014 and our registration details are: registration no SEBI INH200008653, with registration date 19th August, 2021
  2. We have the registration and qualifications required to render the services contemplated under the RA Regulations, and the same are valid and subsisting;
  3. Research analyst services provided by us do not conflict with or violate any provision of law, rule or regulation, contract, or other instrument to which it is a party or to which any of its property is or may be subject;
  4. The maximum fee that may be charged by the RA is ₹1.51 lakhs per annum per family of client. Our current fee structure, the term and duration of our subscription for our Research Services, can be viewed on our website here: https://primeinvestor.in/prime-pricing
  5. The recommendations provided by us as part of the Research Services do not provide any assurance of returns.

5. Consideration and mode of payment

The client shall duly pay to the RA the agreed fees for the services that RA renders to the client and statutory charges, as applicable. Such fees and statutory charges shall be payable through the specified manner and mode(s)/ mechanism(s).

The payment of fees shall be through a mode that shows traceability of funds. Such modes include but are not limited to credit cards/debit cards/ UPI/ net banking or any other mode specified by SEBI from time to time. However, the fees shall not be in cash.

6. Risk factors

  1. Investments are subject to market risk. Investing or trading in financial products involves risk. Past performance of the recommendation is not an indication of future returns. Past performance of the RA is not an indicator of future performance. Past performance of the security is not an indication of future returns.
  2. There are no assurances or guarantees that the objectives of any investment in financial products will be achieved.
  3. The names of financial products mentioned herein do not in any manner indicate their prospects or returns. The performance in the equity may be adversely affected by the performance of individual companies, changes in the market place and industry specific and macro-economic factors.
  4. The performance of the investments/ products recommended by the RA are subject to a wide range of risks, including but not limited to: performance of the respective companies, changes in equity and debt market conditions, micro and macro factors and forces affecting equity and debt markets, general levels of interest rates and interest rate risk, credit risk, liquidity risk, reinvestment risk, economic slowdown, volatility & illiquidity of the stocks, risks associated with trading volumes, liquidity and settlement systems in equity and debt markets and/or such other circumstance beyond the control of the RA or any of its Associates.
  5. Other risk factors include that may affect the performance of the investments/ products recommended by the RA include but are not limited to economic policies, changes of Government and its policies, acts of God, acts of war, civil disturbance, sovereign action and /or such other acts/ circumstance beyond the control of the RA or any of its Associates.
  6. The recommendations provided by the RA as part of its Research Services may not be suitable to all categories of investors.
  7. The client should read all scheme and security related documents carefully before investing.
  8. Returns and performance figures mentioned in the research report represent past performance and should not be constituted to be future returns or guaranteed returns.

7. Conflict of interest

The RA shall adhere to the applicable regulations/ circulars/directions specified by SEBI from time to time in relation to disclosure and mitigation of any actual or potential conflict of interest. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

General disclosures: PrimeInvestor Financial Research Pvt Ltd (with brand name PrimeInvestor) is an independent research entity offering research services on personal finance products to customers. We are a SEBI registered Research Analyst (Registration: INH200008653). PrimeInvestor Financial Research Pvt. Ltd., its employees, directors or agents, do not have any material adverse disciplinary history as on the date of publication of this report.

Restrictions on trading: To ensure no conflict of interest, the RA declares as follows:

  1. Personal trading activities of the individuals employed as research analysts shall be monitored, recorded and subject to a formal approval by the directors or compliance officer of PrimeInvestor Financial Research Private Limited.
  2. Research analysts employed by PrimeInvestor Financial Research Private Limited or their associates or relatives shall not:
    • Deal/ trade in stocks recommended/ tracked by the research analyst within 30 days before and five days after the publication of a research report;
    • Deal/ trade in securities that the research analyst reviews in a manner contrary to the given recommendation;
    • Purchase or receive securities of the issuer before the issuer's initial public offering, if the issuer is principally engaged in the same types of business as companies that the research analyst follows or recommends.

Disclosures with respect to Research and Recommendations Services:

  1. The RA or its directors or any of its officer/employee does not trade in securities which are subject matter of recommendation.
  2. The RA, or any of its officers, directors, employees, or subsidiaries have not received any compensation/ benefits whether monetary or in kind, from the AMC, company, government, bank or any other product manufacturer or third party, whose products are the subject of its Research Services or investment information.
  3. The Research Analysts who have prepared the research reports that form part of the Research Services (“Research Analyst”) certify that all of the views expressed in the research report accurately reflect their views about the subject company or subject security.
  4. The RA or directors or employees or Research Analyst certify that no part of their compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.
  5. The Research Analyst has not served as director, officer or employee in the subject company, AMC or insurance company of the mutual fund or insurance policy that is the subject of this report, or company whose bonds, NCDs, fixed deposits or other savings products that is the subject of this report.
  6. The Research Analyst or their relatives do not have any known direct or indirect material conflict of interest including long/short positions in the subject company.
  7. The Research Analyst may hold investments in the stocks, mutual fund schemes, bonds, fixed deposits, insurance policies, or other products that are the subject of the recommendations provided as part of the Research Services. The Research Analyst certifies that they will not act in a manner contrary to their views on these securities except in the event of significant news or event or change in personal financial circumstances and without formal approval from the directors of PrimeInvestor Financial Research Pvt. Ltd. or the compliance officer.
  8. There are no actual or potential conflicts of interest arising from any connection to or association with any issuer of products/ securities, including any material information or facts that might compromise its objectivity or independence in the carrying on of the Research Services. Such conflict of interest shall be disclosed to the client as and when they arise.
  9. The RA or its directors or its employee or its associates have not managed or co-managed the public offering of any company. The RA or its directors or its employee or its associates have not received any compensation for investment banking or merchant banking of brokerage services from the subject company. The RA or its directors or its employee or its associates have not received any compensation for products or services other than above from the subject company. The RA or its directors or its employee or its associates have not received any compensation or other benefits from the Subject Company or 3rd party in connection with the research report/ recommendation.
  10. The subject company of its research recommendations was not a client of the RA or its directors or its employee or its associates during twelve months preceding the date of recommendation services provided.
  11. The RA or its directors or its employee or its associates has not served as an officer, director or employee of the subject company. Research Analysts has not been engaged in market making activity of the subject company.

PrimeInvestor Financial Research Pvt. Ltd., its Associates, the Research Analysts or their relatives holds ownership of 1% or more, in respect of the said issuer company(ies)? – NO

8. Termination of service and refund of fees:

The RA may terminate or suspend rendering of Research Services to the client in the following circumstances:

  1. On account of suspension/cancellation of registration of RA by SEBI. In case of suspension of certificate of registration of the RA for more than 60 (sixty) days or cancellation of the RA registration, RA shall refund the fees, on a pro rata basis for the period from the effective date of cancellation/ suspension to end of the client’s subscription period.
  2. The RA voluntarily chooses to terminate its Research Service. In the event of such termination of the Research Service, the RA shall refund the fees, on a pro rata basis for the period from the date of such termination of research service to end of the client’s subscription period.

9. Grievance redressal and dispute resolution:

Any grievance related to:

  1. nonreceipt of research report, or
  2. missing pages or inability to download the entire report, or
  3. any other deficiency in the research services provided by RA

shall be escalated promptly by the client to the person/employee designated by RA, in this behalf as under:

Name: Bhavana Acharya
Designation: Director & Compliance Officer, PrimeInvestor Financial Research Pvt Ltd
Email: [email protected]

The RA shall be responsible to resolve grievances within 7 (seven) business working days or such timelines as may be specified by SEBI under the RA Regulations.

RA shall redress grievances of the client in a timely and transparent manner. Any dispute between the RA and his client may be resolved through arbitration or through any other modes or mechanism as specified by SEBI from time to time.

If the client is not satisfied with the response of the RA, he/she can lodge his/her grievances with SEBI at scores.sebi.gov.in. Alternatively, the client may also write to any of the offices of SEBI. For any queries, feedback or assistance, please contact SEBI Office on Toll Free Helpline at 1800 22 7575 / 1800 266 7575

Details on grievances are available on the Website as follows: https://primeinvestor.in/ra-grievance/

10. Additional clauses:

Scope of the Research Service: The Research Services will be limited to providing independent research recommendation and shall not be involved in any advisory or portfolio allocation services. The Research Services are not meant to be tailor-made or customized solutions that specifically apply to each client based on his/her risk profile.

The RA never guarantees the returns on the recommendation provided. Investor shall take note that investment/trading in stocks/Index or other securities is always subject to market risk. Past performance is never a guarantee of same future results. The RA shall not be responsible for any loss to the Investors.

This service is not directed for access or use by anyone in a country, especially the USA, Canada or the European Union countries, where such use or access is unlawful or which may subject PrimeInvestor Financial Research Pvt Ltd or its affiliates to any registration or licensing requirement.

The Research Service, including recommendations, research reports, updates, and other information will be accessible through the RA’s website https://primeinvestor.in only. Such recommendations and updates will not be provided over phone calls.

Fees: Our current fee structure, the term and duration of our subscription for our Research Service, can be viewed on our website: https://primeinvestor.in/prime-pricing. Eligibility for any discounts is ascertained at the time the client subscribes. Any such discount and its tenure shall be at the discretion of the RA.

Subscription and access to content services fall under the purview of Goods and Services Tax (GST) as per the current indirect taxation policy, Government of India. Unless otherwise indicated, prices stated on our website are exclusive of applicable GST, any applicable value added tax (VAT) or other sales taxes. We are a business-to-consumer (B2C) service provider and we do not commit to provide any input tax credit on GST charged on subscription to our Research Service.

We may change the Subscription Fees and charges then in effect, or add new fees or charges which will take effect at the end of the client’s subscription period, by giving notice in advance and an opportunity to cancel renewal of the subscription.

Subscription Access & Renewal: Subscription to the Website commences immediately on the realisation of payment of the Subscription Fees. Subscriptions are set to be renewed automatically at the end of the subscription period.

Unless the client notifies us before the end of his/her subscription period, or the client cancels the auto-renewal mandate within the period specified by law, that the client does not wish to renew his/her subscription, the client’s subscription will renew for the period defined by the client’s subscription plan. We will charge the subscription using the same payment method that you previously used.

Although the client may notify to us his/her intention to his/her subscription, such notice will only take effect at the end of his/her then current subscription period, and he/she will not receive a refund other than as set out under Clause 8 in these Terms.

The client may notify us of his/her wish to cancel his/her subscription by sending an email to [email protected]. The client must provide at least 5 business days advance notice for this to be implemented.

Refunds: There can be no cancellation and refund of subscription fee paid once the subscription is active, other than as stated in Clause 8 of these Terms. If the client is entitled to a refund as specified under Clause 8 of these Terms, the RA will credit that refund to the card or other payment method used by the client to submit payment, unless it has expired - in which case the RA will contact the client to proceed with the refund. If we do issue a refund or credit due to circumstances outside the obligations specified under Clause 8, we are under no obligation to issue the same or a similar refund in the future.

General disclaimers: The recommendations made herein in the Research Services are expression of views and/or opinions and should not be deemed or construed to be advice for the purpose of purchase or sale of any security, nor a solicitation or offering on any investment/ trading opportunity on behalf of the company, AMC, insurance company, or issuer of security referred to herein.

The content and research reports generated by the RA does not constitute or is not intended to constitute an offer to buy or sell, or a solicitation to an offer to buy or sell financial products, units or securities.

The information/ opinion/ views mentioned in research reports or by the RA are not meant to serve as a professional guide to the client or recipients of this Report. The research report, recommendation, or any other content published by the RA do not assure or guarantee any minimum or fixed returns to the client or recipients of the reports/ recommendations/ content.

Use of this information is at the client’s own risk. The client must make his/ her own investment decisions based on his/her specific investment objective and financial position and using such independent advisors as he/she believes necessary. The services rendered by the RA are on a best-effort basis. All information in the content or research report of the RA is provided on an as is basis. Information is believed to be reliable but the RA does not warrant its completeness or accuracy and expressly disclaim all warranties and conditions of any kind, whether express or implied.

While due care has been taken to ensure that the disclosures, information, and opinions given are fair and reasonable, PrimeInvestor Financial Research Pvt Ltd and/or none of its officers, directors, partners, employees, agents, subsidiaries, affiliates or business associates shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information/ opinions/ views contained in the research report and recommendations that form part of the Research Service, and/or mails, social media or notifications issued by PrimeInvestor Financial Research Pvt Ltd or any other agency appointed/authorised by PrimeInvestor Financial Research Pvt Ltd. Returns and performance figures mentioned in the research report represent past performance and should not be constituted to be future returns or guaranteed returns.

Any agreements, transactions or other arrangements made between the client and any third party named on (or linked to from) the Website are at your own responsibility and entered into at your own risk. Any information that you receive via the Website, whether or not it is classified as “real time”, may have stopped being current by the time it reaches you. Market price information may be rounded up/down and therefore may not be entirely accurate.

The purpose of these disclosures is to provide essential information about the Research Services in a manner to assist and enable the prospective client/client in making an informed decision for engaging in Research Services before onboarding.

History, present business and background: PrimeInvestor Financial Research Private Limited is registered with SEBI as Research Analyst with registration no. INH200008653. The Research Analyst got its registration on August 19, 2021 and is engaged in offering research and recommendation services.

Disciplinary history: There are no pending material litigations or legal proceedings against the Research Analyst. As on date, no penalties / directions have been issued by SEBI under the SEBI Act or Regulations made thereunder against the Research Analyst relating to Research Analyst services.

Details of the RA's associates: No associates.

Usage of Website Content: This Website is controlled and operated by the RA. All material, including research reports, recommendations, portfolios, ratings, lists of financial products, illustrations, statements, opinions, views, photographs, products, images, artwork, designs, text, graphics, logos, button icons, images, audio and video clips and software (collectively, “Content”) are protected by copyrights, trademarks and other intellectual property rights that are owned and controlled by the RA or by other parties that have licensed their material to us.

Except where otherwise agreed in writing with the RA, material on the Website is solely for the client’s personal, non-commercial use. Except as provided below, the client must not copy, reproduce, republish, upload, post, transmit or distribute such material in any way, including by e-mail or other electronic means and whether directly or indirectly and the client must not assist any other person to do so.

Without the prior written consent of the RA, modification of the materials, use of the materials on any other web site or networked computer environment or use of the materials for any purpose other than personal, non-commercial use is a violation of the copyrights, trademarks and other proprietary rights, and is prohibited. Any use for which the client receives any remuneration, whether in money or otherwise, is a commercial use for the purposes of these Terms.

The client may occasionally distribute a copy of a research report, or a portion of the same, from the Website in non-electronic form to a few individuals without charge, provided the client includes all copyright and other proprietary rights notices in the same form in which the notices appear, original source attribution, and the phrase “Used with permission from PrimeInvestor Financial Research Pvt. Ltd.”

While the client may occasionally download and store research reports or information from the Website for his/her personal use, he/she may not otherwise provide others with access to the same. The foregoing does not apply to any sharing functionality we provide through the Website that expressly allows the client to share Content or links to Content with others. In addition, the client may not use Content he/she has downloaded for personal use to develop or operate an automated trading system or for data or text mining.

The client agrees not to rearrange or modify the Content available through the Website. The client agrees not to display, post, frame, or scrape the Content for use on another website, app, blog, product or service, except as otherwise expressly permitted by these Terms. You agree not to create any derivative work based on or containing the research products and Content. The framing or scraping of or in-line linking to the Services or any Content contained thereon and/or the use of webcrawler, spidering or other automated means to access, copy, index, process and/or store any Content made available on or through the Services other than as expressly authorized by us is prohibited.

The client further agrees to abide by exclusionary protocols (e.g., Robots.txt, Automated Content Access Protocol (ACAP), etc.) that may be used in connection with the Research Services. The client may not access parts of the Research Services to which he/she is not authorized, or attempt to circumvent any restrictions imposed on your use or access of the Services.

As a general rule, the client may not use the Content, including without limitation, any Content made available through one of our RSS Feeds, in any commercial product or service, without our express written consent.

The client may not create apps, extensions, or other products and services that use our Content without our permission. The client may not aggregate or otherwise use our Content in a manner that could reasonably serve as a substitute for a subscription to the Website.

The client may not access or view the Services with the use of any scripts, extensions, or programs that alter the way the Services are displayed, rendered, or transmitted to you without our written consent.

The client agrees not to use the Services for any unlawful purpose. We reserve the right to terminate or restrict the client's access to the Website if, in our opinion, the client's use of the Services may violate any laws, regulations or rulings, infringe upon another person's rights or violate these Terms.

Prohibited content: The Website includes comments sections, blogs and other interactive features that allow interaction among clients and between clients and the RA. We call the information posted by or contributed by users “Contributed Content.” In the course of availing of the Research Services or uploading any post or comment on the Website, the client shall not post any Contributed Content that (i) contains nude, semi-nude, sexually suggestive photos, (ii) tends or is likely to abuse, harass, threaten, impersonate or intimidate other users of the Website and/or Research Services, (iii) is lascivious or appeals to the prurient interest or if its effect is such as to tend to deprave and corrupt persons who are likely to use or have access to the Website and/or Services, or (iv) otherwise violates, is prohibited or restricted by applicable law, rule or regulation, is offensive or illegal or violates the rights of, harms or threatens the safety of other users of the Website and/or Services (collectively “Prohibited Content”).

We reserve the right to cease to provide the client with the Research Services or access to the Website, or terminate your subscription, with immediate effect and without notice and liability, for violating these Terms, applicable law, rules or regulations and reserves the right to remove Prohibited Content which is in violation of these Terms, or is otherwise abusive, illegal or disruptive. The determination of whether any content constitutes Prohibited Content, violates these Terms, or is otherwise abusive illegal or disruptive, is subject to the sole determination of the Firm.

Changes to Research Services: We are constantly endeavouring to improve the quality of Research Services provided to our clients. Due to this, the form and nature of the Research Services provided may change from time to time without any prior notice to the client. We reserve the right to introduce and initiate new features, functionalities, components to the Website and/or Research Services and/or change, alter, modify, or discontinue existing ones without any prior notice to the client.

Warranty and liability disclaimer: The Website, Research Services, and all the materials and services, included on or otherwise made available to the client through this Website is provided by the RA on an “as is” and “as available” basis without any representation or warranties, express or implied except otherwise specified in writing. Without prejudice to the foregoing paragraph, the RA does not warrant that:

  • This Website and/or Research Services will be constantly available, or available at all;
  • The information on this Website or provided through the Research Services is complete, true, accurate or not misleading; or
  • The quality of any products, services, information, or other material that you obtain through the Website or Services will meet your expectations.

The RA, to the fullest extent permitted by law, disclaims all warranties, whether express or implied, including the warranty of merchantability, fitness for particular purpose and non-infringement. The RA makes no warranties about the accuracy, reliability, completeness, or timeliness of the Website, Research Services, Content, Contributed Content, Services, software, text, graphics and links.

The RA does not warrant that this Website, Research Services, information, content, materials, or any other material included on or otherwise made available to you through this Website, their servers, or electronic communication sent by the RA are free of viruses or other harmful components.

Nothing on this Website constitutes, or is meant to constitute, advice of any kind.

Indemnification: The client:

  1. Represents, warrants and covenants that no materials of any kind provided by him/her will:
    1. Violate, plagiarise, or infringe upon the rights of any third party, including copyright, trademark, privacy or other personal or proprietary rights; or
    2. Contain libellous, Prohibited Content or other unlawful material;
  2. Hereby agree to indemnify, defend and hold harmless the RA and all of the RA’s officers, directors, owners, agents, customers/clients, information providers, affiliates, licensors and licensees (collectively, the “Indemnified Parties”) from and against any and all liability and costs, including, without limitation, reasonable advocate’s fees, incurred by the Indemnified Parties in connection with any claim arising out of any breach by the client of these Terms or the foregoing representations, warranties and covenants. The client shall cooperate as fully as reasonably required in the defence of any such claim. The RA reserves the right, at its own expense, to assume the exclusive defence and control of any matter subject to indemnification by the client.

Applicable law: This Website, including the Content and Contributed Content and information contained herein, and the provision of Research Services shall be governed by the Securities and Exchange Board of India, laws of the Republic of India and the courts of Chennai, India which shall retain exclusive jurisdiction to entertain any proceedings in relation to any disputes arising out of the same. As such, the laws of India shall govern any transaction completed using this Website.

Information gathered and tracked: Information submitted or collected on the Website or pursuant to the use of the Services is stored in a database. Specifically, we store the username, name, e-mail address, contact number, as submitted or collected on our Website or through the provision of the Research Services. We may use such information to send out occasional promotional materials, including alerts on new Services available, or other promotional and marketing material relating to our clients and customers.

In accordance with the Information Technology Act 2000, the name and the details of the Grievance Officer at PrimeInvestor is provided below:

Mr. Srikanth Meenakshi
PrimeInvestor Financial Research Pvt. Ltd., Registered office: 659, 4th Avenue, D-Sector, Anna Nagar Western Extension, Chennai 600 101.
Email: [email protected]

11. Mandatory notice:

Clients shall be requested to go through Do’s and Don’ts while dealing with RA as specified in SEBI master circular no. SEBI/HO/MIRSD-POD-1/P/CIR/2024/49 dated May 21, 2024 or as may be specified by SEBI from time to time.

12. Optional Centralised Fee Collection Mechanism:

SEBI has operationalized a centralized fee collection mechanism for IA and RA. Under this mechanism, clients shall pay fees to IAs/RAs through a designated platform/portal administered by a recognized Administration and Supervision body. This is an optional mechanism for the registered entities. At this time, PrimeInvestor has opted out of this fee collection mechanism. Therefore, all subscription payments for the Research Services will be through the modes as specified in Clause 5 of these Terms.

Enter the OTP sent to (Edit)
By doing this you agree to our terms & conditions
Didn't receive OTP? Resend

Have an account?
Login To Your Account
OR
Don’t have an account ? Register for free